BioAge Labs (BIOA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.58
- Estimate
- -$0.62
- Surprise
- +7.1%
- Revenue (period 2026-06-30)
- $2.5M
- Score today
- 3.2/10
Revenue source: xbrl.
How the report landed
BioAge Labs (BIOA) reported a narrower loss than forecast — diluted EPS of -$0.58 against the -$0.62 estimate (a 7.1% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates BIOA Sell at 3.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +7.1% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $35.62 vs price $9.48 — ratio 3.8×). Rejected, falling back to technical TP.
- Quality below floor (1.8 < 4.0)
- Momentum score 2.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.80
- Price target
- $24.41
- Stop
- $8.82
- Upside to target
- +149.1%
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
BIOA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $435.1M
- P/E (fwd)
- -4.0
- 52-week range
- $4.42–$25.95
- Off 52-week high
- 62.2%
- RSI (14)
- 36
- Volume vs avg
- 0.33×
- Score today
- 3.2/10